Feb 20 (Reuters) - Bavarian Nordic A/S:
* REG-BAVARIAN NORDIC ANNOUNCES ANNUAL REPORT 2019
* ACQUISITION OF RABIPUR/RABAVERT AND ENCEPUR WILL HAVE A SIGNIFICANT POSITIVE IMPACT ON BAVARIAN NORDIC’S REVENUE, AS VACCINES WILL BECOME PRIMARY REVENUE DRIVER
* BAVARIAN NORDIC DOES NOT ANTICIPATE STOCK-OUTS TO AFFECT SALES IN 2020 AND THUS MAINTAIN EXPECTATIONS TO GROW COMBINED SALES OF NEW PRODUCTS BY A LOW-TO-MID SINGLE DIGIT RATE ANNUALLY FROM PREVIOUS ESTIMATED 2019 LEVEL
* BAVARIAN NORDIC DOES NOT ANTICIPATE STOCK-OUTS TO AFFECT SALES IN 2020
* ACQUISITION OF RABIPUR/RABAVERT AND ENCEPUR WILL HAVE A SIGNIFICANT POSITIVE IMPACT ON BAVARIAN NORDIC’S 2020 REVENUE, AS VACCINES WILL BECOME PRIMARY REVENUE DRIVER
* - MAINTAIN EXPECTATIONS TO GROW COMBINED SALES OF NEW PRODUCTS BY A LOW-TO-MID SINGLE DIGIT RATE ANNUALLY FROM PREVIOUS ESTIMATED 2019 LEVEL.
* EXPECTS 2020 EBITDA OF DKK 675 MILLION
* FY REVENUE DKK 662.5 MILLION VERSUS DKK 500.6 MILLION YEAR AGO
* RESEARCH AND DEVELOPMENT COSTS OF APPROXIMATELY DKK 500 MILLION ARE EXPECTED FOR 2020
* FY EBIT LOSS DKK 328.4 MILLION VERSUS LOSS DKK 354.5 MILLION YEAR AGO
* IN ADDITION TO SALES FROM RABIPUR/RABAVERT AND ENCEPUR GUIDANCE ALSO ASSUMES REVENUE FROM OUR SMALLPOX VACCINE BUSINESS, A MILESTONE PAYMENT FROM JANSSEN RELATED TO EXPECTED EMA APPROVAL OF EBOLA VACCINE AND OTHER REVENUE FROM CONTRACT WORK
* 2020 OUTLOOK: APPROXIMATE REVENUE OF DKK 1,900 MILLION
* COMPANY IS PLANNING A RIGHTS ISSUE ON NASDAQ COPENHAGEN IN FIRST HALF OF 2020
* RIGHTS ISSUE, WHICH HAS BEEN APPROVED BY COMPANY’S SHAREHOLDERS, IS FULLY UNDERWRITTEN BY CITI AND NORDEA AS JOINT GLOBAL COORDINATORS. Source text for Eikon: Further company coverage: (Gdansk Newsroom)
Our Standards: The Thomson Reuters Trust Principles.